Related Experiment Videos
Clinical use of serum digoxin concentrations
1Division of Cardiology, Ohio State University, Columbus 43210.
The American Journal of Cardiology
|June 4, 1992
Summary
The radioimmunoassay for digoxin, developed in 1969, has improved digitalis therapy by defining pharmacokinetics and reducing toxicity. Understanding its pharmacodynamics and assay limitations is crucial for proper use.
Area of Science:
- Pharmacology
- Clinical Chemistry
Background:
- The radioimmunoassay for digoxin revolutionized digitalis therapy since its 1969 development.
- Defined pharmacokinetics of digoxin have led to a significant decrease in digitalis toxicity.
Purpose of the Study:
- To elucidate the relationship between pharmacokinetic parameters and pharmacodynamics of digoxin.
- To understand the limitations of the digoxin assay for optimal clinical application.
Main Methods:
- Utilizing systolic time intervals (STI) to quantify the inotropic effects of digitalis.
- Establishing a mathematical relationship between STI and serum digoxin concentrations.
- Employing computer simulations to predict the impact of dosing adjustments.
Main Results:
- Systolic time intervals (STI) effectively quantify digitalis inotropic effects for both oral and IV administration.
- Mathematical modeling allows for simulation of digoxin dosing effects on concentrations.
- Identified assay limitations include quality control issues, metabolite interference, and cross-reactions.
Conclusions:
- Proper use of the digoxin assay requires understanding its pharmacokinetic-pharmacodynamic relationship and limitations.
- Factors like physical activity and drug interactions can influence serum digoxin concentrations.
- Further testing and refinement of computer surveillance methods are needed for widespread acceptance.